{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T12:10:04Z","timestamp":1739103004011,"version":"3.37.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1007\/bf03041035","type":"journal-article","created":{"date-parts":[[2009,5,14]],"date-time":"2009-05-14T01:49:57Z","timestamp":1242265797000},"page":"515-536","source":"Crossref","is-referenced-by-count":4,"title":["Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)","Pathogenese, Klassifikation und Therapie der myelodysplastischen Syndrome"],"prefix":"10.1007","volume":"115","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Wimazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Schwarzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03041035_CR1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM196304112681504","volume":"28","author":"JJ Rheingold","year":"1963","unstructured":"Rheingold JJ, Kaufman R, Adelson E, Lear A (1963) Smouldering acute leukemia. N Engl J Med 28: 812\u2013816","journal-title":"N Engl J Med"},{"key":"BF03041035_CR2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7326\/0003-4819-93-2-347","volume":"93","author":"HP Koeffler","year":"1980","unstructured":"Koeffler HP, Golde DW (1980) Human preleukemia, Ann Int Med 93: 347\u2013353","journal-title":"Ann Int Med"},{"key":"BF03041035_CR3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood.V61.6.1035.1035","volume":"61","author":"PL Greenberg","year":"1983","unstructured":"Greenberg PL (1983) The smouldering myeloid leukemic states: clinical and biologic features. Blood 61: 1035\u20131044","journal-title":"Blood"},{"key":"BF03041035_CR4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.1985.tb07361.x","volume":"59","author":"G Tricot","year":"1985","unstructured":"Tricot G, Boogaerts MA, de Wolf-Peeters C, van den Berghe H, Verwilghen RL (1985) The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 59: 659\u2013670","journal-title":"Br J Haematol"},{"key":"BF03041035_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.me.42.020191.001523","volume":"42","author":"WS Beck","year":"1991","unstructured":"Beck WS (1991) Diagnosis of megaloblastic anemia. Annu Rev Med 42: 311\u2013322","journal-title":"Annu Rev Med"},{"key":"BF03041035_CR6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/bmj.314.7078.430","volume":"314","author":"V Hoffbrand","year":"1997","unstructured":"Hoffbrand V, Provan D (1997) ABC of clinical haematology. Macrocytic anaemias, BMJ 314: 430\u2013433","journal-title":"BMJ"},{"key":"BF03041035_CR7","first-page":"23","volume-title":"The Myelodysplastic Syndrome","author":"RA Cartwright","year":"1992","unstructured":"Cartwright RA (1992) Incidence and epidemiology of the myelodysplastic sydromes. In: Multi GJ, Galton DAG (eds) The Myelodysplastic Syndrome. Churchill Livingston. Edinburgh, pp 23\u201331"},{"key":"BF03041035_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0145-2126(94)00152-Z","volume":"19","author":"P Cole","year":"1995","unstructured":"Cole P, Sateren W, Delzell E (1995) Epidemiologic perspectives on myelodysplastic syndromes and leukemia. Leuk Res 19: 361\u2013365","journal-title":"Leuk Res"},{"key":"BF03041035_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF02994001","volume":"73","author":"C Aul","year":"2001","unstructured":"Aul C, Giagounidis A, Germing U (2001) Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73: 405\u2013410","journal-title":"Int J Hematol"},{"key":"BF03041035_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0145-2126(92)90106-H","volume":"16","author":"T Hamblin","year":"1992","unstructured":"Hamblin T (1992) Clinical features in MDS. Leuk Res 16: 89\u201393","journal-title":"Leuk Res"},{"key":"BF03041035_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189\u2013199","journal-title":"Br J Haematol"},{"key":"BF03041035_CR12","first-page":"95","volume":"33","author":"PA Kouides","year":"1996","unstructured":"Kouides PA, Bennett JM (1996) Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 33: 95\u2013110","journal-title":"Semin Hematol"},{"key":"BF03041035_CR13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","volume":"87","author":"JM Bennett","year":"1994","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 87: 746\u2013754","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"BF03041035_CR14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000205910","volume":"87","author":"C Sultan","year":"1987","unstructured":"Sultan C, Imbert M, Jouault H, Scoazec JY (1987) Myelodysplastic syndromes. Acta Haematol 87 [Suppl 1]: 91\u201393","journal-title":"Acta Haematol"},{"key":"BF03041035_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0609.1984.tb00695.x","volume":"32","author":"T Ruutu","year":"1984","unstructured":"Ruutu T, Partanen S, Lintula R, Teerenhovi L, Knuutila S (1984) Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand J Haematol 32: 395\u2013402","journal-title":"Scand J Haematol"},{"key":"BF03041035_CR16","first-page":"1063","volume":"14","author":"GB Tennant","year":"1986","unstructured":"Tennant GB, Jacobs A, Baily-Wood R (1986) Peripheral blood granulocyte-macrophage progenitors in patients with the myelodysplastic syndromes. Exp Hematol 14: 1063\u20131068","journal-title":"Exp Hematol"},{"key":"BF03041035_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00320634","volume":"57","author":"K Geissler","year":"1988","unstructured":"Geissler K, Hinterberger W, Jager U, Bettelheim P, Neumann E, Haas O, Ambros P, Chott A, Radaszkiewicz T, Lechner K (1988) Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. Blut 57: 45\u201349","journal-title":"Blut"},{"key":"BF03041035_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0145-2126(88)90055-0","volume":"12","author":"K Geissler","year":"1988","unstructured":"Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K (1988) Colony growth characteristic in chronic myelomonocytic leukemia. Leuk Res 12: 373\u2013377","journal-title":"Leuk Res"},{"key":"BF03041035_CR19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03041036","volume":"115","author":"L \u00d6hler","year":"2003","unstructured":"\u00d6hler L, Geissler K, Hinterberger W (2003) Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr 115: 537\u2013546","journal-title":"Wien Klin Wochenschr"},{"key":"BF03041035_CR20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V63.3.634.634","volume":"63","author":"P Solal-Celigny","year":"1984","unstructured":"Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, Brousse N, Mancilla F, Renoux M, Bernard JF, et al (1984) Chronic myelomonocytic leukemia according to the FAB classification: analysis of 35 cases. Blood 63: 634\u2013638","journal-title":"Blood"},{"key":"BF03041035_CR21","first-page":"1268","volume":"6","author":"GE Verhoef","year":"1992","unstructured":"Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA (1992) Measurement of serum cytokine levels in patients with myelo-dysplastic syndromes. Leukemia 6: 1268\u20131272","journal-title":"Leukemia"},{"key":"BF03041035_CR22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1365-2141.2001.02921.x","volume":"114","author":"S Verstovsek","year":"2001","unstructured":"Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukemia and advanced myelodysplastic syndrome. Br J Haematol 114: 290\u2013295","journal-title":"Br J Haematol"},{"key":"BF03041035_CR23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/1042819021000039965","volume":"43","author":"WR Sperr","year":"2002","unstructured":"Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, J\u00e4ger U, Geissler K, Greschniok A, Horny H-P, Lechner K, Valent P (2002) Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 43: 1097\u20131105","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2141.1984.tb02916.x","volume":"57","author":"G Tricot","year":"1984","unstructured":"Tricot G, de Wolf-Peters C, Hendrickx B, Verwilghen RL (1984) Bone marrow histology in myelodysphastic syndromes. Br J Haematol 57: 423\u2013430","journal-title":"Br J Haematol"},{"key":"BF03041035_CR25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ajcp\/87.2.180","volume":"87","author":"F Delacretaz","year":"1987","unstructured":"Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J (1987) Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsies. Am J Clin Pathol 87: 180\u2013186","journal-title":"Am J Clin Pathol"},{"key":"BF03041035_CR26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","volume":"81","author":"G Pruneri","year":"1999","unstructured":"Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81: 1398\u20131401","journal-title":"Br J Cancer"},{"key":"BF03041035_CR27","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","volume":"96","author":"A Aguayo","year":"2000","unstructured":"Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O\u2019Brien S, Keating M, Freireich E, Albitar M (2000) Angiogenesis in acute and chronic leukemias and myelodysplatic syndromes. Blood 96: 2240\u20132245","journal-title":"Blood"},{"key":"BF03041035_CR28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V79.1.198.198","volume":"79","author":"MH Mangi","year":"1992","unstructured":"Mangi MH, Mufti GJ (1992) Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79: 198\u2013205","journal-title":"Blood"},{"key":"BF03041035_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jcp.48.4.291","volume":"48","author":"H-P Horny","year":"1995","unstructured":"Horny H-P, Wehrmann M, Schlicker HUH, Eichstaedt A, Clemens MR, Kaiserling E (1995) QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. J Clin Pathol 48: 291\u2013294","journal-title":"J Clin Pathol"},{"key":"BF03041035_CR30","first-page":"25","volume":"19","author":"PC Nowell","year":"1992","unstructured":"Nowell PC (1992) Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 19: 25\u201333","journal-title":"Semin Oncol"},{"key":"BF03041035_CR31","first-page":"127","volume":"33","author":"P Fenaux","year":"1996","unstructured":"Fenaux P, Morel P, Lai JL (1996) Cytogenetics of myelodysplastic syndromes. Semin Hematol 33: 127\u2013138","journal-title":"Semin Hematol"},{"key":"BF03041035_CR32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0145-2126(92)90097-Q","volume":"16","author":"GJ Mufti","year":"1992","unstructured":"Mufti GJ (1992) Chromosomal deletions in the myelodysplastic syndromes. Leuk Res 16: 35\u201341","journal-title":"Leuk Res"},{"key":"BF03041035_CR33","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","volume":"84","author":"J Boultwood","year":"1994","unstructured":"Boultwood J, Lewis S, Wainscoat JS (1994) The 5q-syndrome. Blood 84: 3253\u20133260","journal-title":"Blood"},{"key":"BF03041035_CR34","first-page":"2174","volume":"8","author":"J Cortes","year":"1994","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E (1994) Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute leukemias and myelodysplastic syndromes. Leukemia 8: 2174\u20132178","journal-title":"Leukemia"},{"key":"BF03041035_CR35","first-page":"111","volume":"33","author":"S Rosati","year":"1996","unstructured":"Rosati S, Anastasi J, Vardiman J (1996) Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Seminars Hematol 33: 111\u2013126","journal-title":"Seminars Hematol"},{"key":"BF03041035_CR36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0145-2126(96)00028-8","volume":"20","author":"R Neuwirtova","year":"1996","unstructured":"Neuwirtova R, Mocikova K, Musilova J, Jelinek J, Havlicek F, Michalova K, Adamkov M (1996) Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 20: 717\u2013726","journal-title":"Leuk Res"},{"key":"BF03041035_CR37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0145-2126(01)00040-6","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP, Bennett JM (2001) Myelomastocytic overlap syndromes: Biology, criteria, and relationship to mastocytosis. Leuk Res 25: 595\u2013602","journal-title":"Leuk Res"},{"key":"BF03041035_CR38","unstructured":"Vardiman JW (2001) Myelodysplastic\/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues, Vol 1, pp 45\u201359"},{"key":"BF03041035_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/10428199209049817","volume":"8","author":"G Lambertenghi-Delitiers","year":"1992","unstructured":"Lambertenghi-Delitiers G, Annaloro C, Oriani A, Soligo D (1992) Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk Lymphoma 8: 51\u201355","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01697619","volume":"66","author":"H Maschek","year":"1993","unstructured":"Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K, Dietzfelbinger M, Georgii A (1993) Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 66: 117\u2013122","journal-title":"Ann Hematol"},{"key":"BF03041035_CR41","first-page":"1037","volume":"15","author":"EG Levine","year":"1986","unstructured":"Levine EG, Bloomfield CD (1986) Secondary myelodysplastic syndromes and lekaemias. Clin Hematol 15: 1037\u20131080","journal-title":"Clin Hematol"},{"key":"BF03041035_CR42","first-page":"23","volume":"27","author":"A Zeidman","year":"1995","unstructured":"Zeidman A, Dayan DB, Mittleman M (1995) Secondary myelodysplastic syndromes and acute leukemias. Hematologia (Budapest) 27: 23\u201328","journal-title":"Hematologia (Budapest)"},{"key":"BF03041035_CR43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0145-2126(95)00049-T","volume":"19","author":"JM Bennett","year":"1995","unstructured":"Bennett JM (1995) Secondary acute myeloid leukemia. Leuk Res 19: 231","journal-title":"Leuk Res"},{"key":"BF03041035_CR44","first-page":"71","volume":"83","author":"C Aul","year":"1998","unstructured":"Aul C, Bowen DT, Yoshida Y (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83: 71\u201386","journal-title":"Haematologica"},{"key":"BF03041035_CR45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.leu.2401618","volume":"14","author":"C Rosenfeld","year":"2000","unstructured":"Rosenfeld C, List A (2000) A hypothesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14: 2\u20138","journal-title":"Leukemia"},{"key":"BF03041035_CR46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4615-1463-3_11","volume":"108","author":"HD Preisler","year":"2001","unstructured":"Preisler HD (2001) Evolution of secondary hematologic disorders: preMDS\u2192MDS\u2192sAML. Cancer Treat Res 108: 185\u2013230","journal-title":"Cancer Treat Res"},{"key":"BF03041035_CR47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/22780","volume":"400","author":"WC Hahn","year":"1999","unstructured":"Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA (1999) Creation of human tumor cells with defined genetic elements. Nature 400: 464\u2013468","journal-title":"Nature"},{"key":"BF03041035_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0145-2126(98)00112-X","volume":"22","author":"PL Greenberg","year":"1998","unstructured":"Greenberg PL (1998) Apoptosis and its role in myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 22: 1123\u20131136","journal-title":"Leuk Res"},{"key":"BF03041035_CR49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0145-2126(99)00094-6","volume":"23","author":"Y Yoshida","year":"1999","unstructured":"Yoshida Y, Mufti GJ (1999) Apoptosis and its significance in MDS: controversies revisited. Leuk Res 23: 777\u2013785","journal-title":"Leuk Res"},{"key":"BF03041035_CR50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF02994003","volume":"73","author":"JE Parker","year":"2001","unstructured":"Parker JE, Mufti GJ (2001) The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 73: 416\u2013428","journal-title":"Int J Hematol"},{"key":"BF03041035_CR51","first-page":"556","volume":"45","author":"P Fenaux","year":"1997","unstructured":"Fenaux P, Preudhomme C (1997) Molecular abnormalities and clonality in myelodysplastic syndromes. Pathol Biol (Paris) 45: 556\u2013560","journal-title":"Pathol Biol (Paris)"},{"key":"BF03041035_CR52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/10428199409056284","volume":"13","author":"IS Weimar","year":"1994","unstructured":"Weimar IS, Bourghis JH, De Gast GC, Gerritsen WR (1994) Clonality in myelodysplastic syndromes. Leu Lymphoma 13: 215\u2013221","journal-title":"Leu Lymphoma"},{"key":"BF03041035_CR53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0889-8588(18)30328-9","volume":"6","author":"CR Bartram","year":"1992","unstructured":"Bartram CR (1992) Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 6: 557\u2013570","journal-title":"Hematol Oncol Clin North Am"},{"key":"BF03041035_CR54","first-page":"99","volume":"57","author":"J Stephenson","year":"1993","unstructured":"Stephenson J, Mufti GJ, Yoshida Y (1993) Myelodysplastic syndromes: from morphology to molecular biology, Part II. The molecular genetics of myelodysplasia. Int J Hematol 57: 99\u2013112","journal-title":"Int J Hematol"},{"key":"BF03041035_CR55","first-page":"1648","volume":"10","author":"A Raza","year":"1996","unstructured":"Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S, Preisler H (1996) A paradigm shift in myelodysplastic syndromes. Leukemia 10: 1648\u20131652","journal-title":"Leukemia"},{"key":"BF03041035_CR56","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.V71.6.1707.1707","volume":"71","author":"J Lyons","year":"1988","unstructured":"Lyons J, Jannsen JW, Bartram C, Layton M, Mufti GJ (1988) Mutations of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 71: 1707\u20131712","journal-title":"Blood"},{"key":"BF03041035_CR57","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0145-2126(96)00008-2","volume":"20","author":"V Shetty","year":"1996","unstructured":"Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20: 891\u2013900","journal-title":"Leuk Res"},{"key":"BF03041035_CR58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10428190009089441","volume":"37","author":"HJ Deeg","year":"2000","unstructured":"Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, Gooley T (2000) Negative regulators of hemopoiesis and stroma function in patients with myclodysplastic syndrome. Leuk Lymphoma 37: 405\u2013414","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02982044","volume":"75","author":"K Allampallam","year":"2002","unstructured":"Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh MW, York A, Raza A (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75: 289\u2013297","journal-title":"Int J Hematol"},{"key":"BF03041035_CR60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/152581602753448586","volume":"11","author":"B Brunner","year":"2002","unstructured":"Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R (2002) Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Haematother Stem Cell Res 11: 119\u2013125","journal-title":"J Haematother Stem Cell Res"},{"key":"BF03041035_CR61","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","volume":"97","author":"WT Bellamy","year":"2001","unstructured":"Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427\u20131434","journal-title":"Blood"},{"key":"BF03041035_CR62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.1990.tb02611.x","volume":"75","author":"LH Coutinho","year":"1990","unstructured":"Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG (1990) Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS) Br J Haematol 75: 16\u201325","journal-title":"Br J Haematol"},{"key":"BF03041035_CR63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/stem.140577","volume":"14","author":"J Gidali","year":"1996","unstructured":"Gidali J, Feher I, Hollan SR (1996) Blast colony forming cell-binding capacity of bone marrow stroma from myelodysplastic syndrome. Stem Cells 14: 577\u2013583","journal-title":"Stem Cells"},{"key":"BF03041035_CR64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0145-2126(98)00163-5","volume":"23","author":"S Aizawa","year":"1999","unstructured":"Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, Nabeshima R, Shima D, Handa H, Toyama K (1999) Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23: 239\u2013246","journal-title":"Leuk Res"},{"key":"BF03041035_CR65","first-page":"1038","volume":"86","author":"S Tauro","year":"2001","unstructured":"Tauro S, Hepburn MD, Bowen DT, Pippard MJ (2001) Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 86: 1038\u20131045","journal-title":"Haematologica"},{"key":"BF03041035_CR66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-4608(00)00347-2","volume":"124","author":"J Kameoka","year":"2001","unstructured":"Kameoka J, Funato T, Obara Y, Kadowaki I, Yokoyama H, Kimura T, Tomiya Y, Yamada M, Ishikawa I, Takagawa M, Sasaki O, Kimura J, Harigae H, Miura I, Meguro K, Kaku M, Sasaki T (2001) Clonal evolution from trisomy into tetrasomy of chromosome 8 associated with the development of acute myeloid leukemia from myelodysplastic syndrome. Cancer Genet Cytogenet 124: 159\u2013164","journal-title":"Cancer Genet Cytogenet"},{"key":"BF03041035_CR67","first-page":"838","volume":"7","author":"A Orazi","year":"1993","unstructured":"Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi-Deliliers G (1993) Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia 7: 838\u2013847","journal-title":"Leukemia"},{"key":"BF03041035_CR68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-4608(91)90246-Q","volume":"55","author":"J Pedersen-Bjergaard","year":"1991","unstructured":"Pedersen-Bjergaard J, Philip P (1991) Two different classes of therapy-related and de novo acute myeloid leukemias? Cancer Genet Cytogenet 55: 119\u2013124","journal-title":"Cancer Genet Cytogenet"},{"key":"BF03041035_CR69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/10428199309054725","volume":"11","author":"M Ellis","year":"1993","unstructured":"Ellis M, Ravid M, Lishner M (1993) A comparative analysis of alkylating agents and epipodophyllotoxin-related leukemias. Leuk Lymphoma 11: 9\u201313","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR70","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood.V86.9.3542.bloodjournal8693542","volume":"86","author":"J Pedersen-Bjergaard","year":"1995","unstructured":"Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86: 3542\u20133552","journal-title":"Blood"},{"key":"BF03041035_CR71","first-page":"483","volume":"83","author":"MK Andersen","year":"1998","unstructured":"Andersen MK, Johansson B, Larson SO, Pedersen-Bjergaard J (1998) Chromosome abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 83: 483\u2013488","journal-title":"Haematologica"},{"key":"BF03041035_CR72","unstructured":"Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues, Vol 1, pp 62\u201373"},{"key":"BF03041035_CR73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.1985.tb07329.x","volume":"59","author":"GJ Mufti","year":"1985","unstructured":"Mufti GJ, Stevens JR, Oseier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425\u2013433","journal-title":"Br J Haematol"},{"key":"BF03041035_CR74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","volume":"74","author":"GF Sanz","year":"1989","unstructured":"Sanz GF, Sanz MA, Vallespi T, Canizo M (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 74: 395\u2013408","journal-title":"Blood"},{"key":"BF03041035_CR75","first-page":"52","volume":"6","author":"C Aul","year":"1992","unstructured":"Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6: 52\u201359","journal-title":"Leukemia"},{"key":"BF03041035_CR76","first-page":"1315","volume":"7","author":"P Morel","year":"1993","unstructured":"Morel P, Hebbar M, Lai JL, Duhamel A (1993) Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia 7: 1315\u20131323","journal-title":"Leukemia"},{"key":"BF03041035_CR77","first-page":"499","volume":"7","author":"K Toyama","year":"1993","unstructured":"Toyama K, Ohyashiki K, Yoshida Y, Abe T (1993) Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia 7: 499\u2013508","journal-title":"Leukemia"},{"key":"BF03041035_CR78","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079\u20132088","journal-title":"Blood"},{"key":"BF03041035_CR79","first-page":"358","volume":"83","author":"GF Sanz","year":"1998","unstructured":"Sanz GF, Sanz MA, Greenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83: 358\u2013368","journal-title":"Haematologica"},{"key":"BF03041035_CR80","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V98.10.2935","volume":"98","author":"T N\u00f6sslinger","year":"2001","unstructured":"N\u00f6sslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, Pittermann E, Pfeilst\u00f6cker M (2001) Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98: 2935\u20132941","journal-title":"Blood"},{"key":"BF03041035_CR81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0145-2126(99)00032-6","volume":"23","author":"JJ Lee","year":"1999","unstructured":"Lee JJ, Kim HJ, Chung IJ, Kim JS, Sohn SK, Kim BS, Lee KH, Kwak JY, Park YH, Ahn JS, Park YS (1999) Comparison of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 23: 425\u2013432","journal-title":"Leuk Res"},{"key":"BF03041035_CR82","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s002770000280","volume":"80","author":"WR Sperr","year":"2001","unstructured":"Sperr WR, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner GH, Schwarzinger I, Haas OA, Geissler K, Lechner K, Valent P (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80: 272\u2013277","journal-title":"Ann Hematol"},{"key":"BF03041035_CR83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0145-2126(00)00140-5","volume":"25","author":"F Wimazal","year":"2001","unstructured":"Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Lechner K, Valent P (2001) Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 25: 287\u2013294","journal-title":"Leuk Res"},{"key":"BF03041035_CR84","first-page":"1906","volume":"8","author":"C Aul","year":"1992","unstructured":"Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W (1992) Risk assessment in primary myelodysplastic syndromes: validation of the D\u00fcsseldorf score. Leukemia 8: 1906\u20131913","journal-title":"Leukemia"},{"key":"BF03041035_CR85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-0-585-38571-6_14","volume":"99","author":"PA Kouides","year":"1999","unstructured":"Kouides PA, Bennett JM (1999) Advances in the therapy of the myelodysplastic syndromes. Cancer Treat Res 99: 335\u2013362","journal-title":"Cancer Treat Res"},{"key":"BF03041035_CR86","first-page":"141","volume":"70","author":"E Hellstrom-Lindberg","year":"1999","unstructured":"Hellstrom-Lindberg E (1999) Treatment of adult myelodysplastic syndromes. Int J Hematol 70: 141\u2013154","journal-title":"Int J Hematol"},{"key":"BF03041035_CR87","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1054\/blre.2000.0139","volume":"14","author":"M Oosterveld","year":"2000","unstructured":"Oosterveld M, de Witte T (2000) Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia. Blood Reviews 14: 182\u2013189","journal-title":"Blood Reviews"},{"key":"BF03041035_CR88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/PL00012086","volume":"6","author":"Y Asano","year":"2001","unstructured":"Asano Y, Niho Y (2001) Treatment of myelodysplastic syndromes. Int J Oncol 6: 74\u201379","journal-title":"Int J Oncol"},{"key":"BF03041035_CR89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s002770100347","volume":"80","author":"W Verbeck","year":"2001","unstructured":"Verbeck W, Ganser A (2001) Evolving treatment options of myelodysplastic syndromes. ann Hematol 80: 499\u2013509","journal-title":"ann Hematol"},{"key":"BF03041035_CR90","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1040-8428(01)00093-2","volume":"40","author":"FD Pisani","year":"2001","unstructured":"Pisani FD, Rainaldi A (2001) Management of high-risk myelodysplastic syndromes. Crit Reviews Oncol\/Hematol 40: 215\u2013228","journal-title":"Crit Reviews Oncol\/Hematol"},{"key":"BF03041035_CR91","first-page":"910","volume":"83","author":"M Cazzola","year":"1998","unstructured":"Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E (1998) A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 83: 910\u2013935","journal-title":"Haematologica"},{"key":"BF03041035_CR92","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1365-2141.1998.00797.x","volume":"102","author":"M Delforge","year":"1998","unstructured":"Delforge M, Demuynck H, Verhoef G, Vandenberghe P, Zachee P, Maertens J, Van Duppen V, Boogaerts MA (1998) Patients with high risk myelodysplastic syndromes can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 102: 486\u2013494","journal-title":"Br J Haematol"},{"key":"BF03041035_CR93","first-page":"1805","volume":"9","author":"T Witte de","year":"1995","unstructured":"de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Sellslag D, Zittoun R, Dardenne M, et al (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more then 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9: 1805\u20131811","journal-title":"Leukemia"},{"key":"BF03041035_CR94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0145-2126(95)00169-7","volume":"20","author":"T Economopoulos","year":"1996","unstructured":"Economopoulos T, Papageorgiou E, Constantinidou M, Parharidou A, Kostourou A, Devenoulas J, Raptis S (1996) Treatment of high risk myelodysplastic syndromes with idarubicine and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 20: 385\u2013390","journal-title":"Leuk Res"},{"key":"BF03041035_CR95","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199905273402107","volume":"340","author":"ML Heaney","year":"1999","unstructured":"Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340: 1649\u20131660","journal-title":"N Engl J Med"},{"key":"BF03041035_CR96","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2006::AID-CNCR18>3.0.CO;2-2","volume":"86","author":"F Ferrara","year":"1999","unstructured":"Ferrara F, Leoni- F, Pinto A, Mirto S, Morra E, Zagonel V, Mele G, Ciolli S, Magrin S, Montillo M (1999) Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 86: 2006\u20132013","journal-title":"Cancer"},{"key":"BF03041035_CR97","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","volume":"93","author":"EH Estey","year":"1999","unstructured":"Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E (1999) Randomized pahse II study of fludarabine+cytosine arabino-side+idarubicin \u00b1all trans retinoic acid \u00b1granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93: 2478\u20132484","journal-title":"Blood"},{"key":"BF03041035_CR98","first-page":"139","volume":"72","author":"M Beran","year":"2000","unstructured":"Beran M (2000) Intensive chemotherapy for patients with high-isk myelodysplastic syndrome. Int J Hematol 72: 139\u2013150","journal-title":"Int J Hematol"},{"key":"BF03041035_CR99","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1990.tb02558.x","volume":"74","author":"T Witte de","year":"1990","unstructured":"de Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J, et al (1990) Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74: 151\u2013155","journal-title":"Br J Haematol"},{"key":"BF03041035_CR100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.leu.2400853","volume":"12","author":"FR Appelbaum","year":"1998","unstructured":"Appelbaum FR, Anderson J (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to the IPSS score. Leukemia 12: S 25\u201329","journal-title":"Leukemia"},{"key":"BF03041035_CR101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1054\/blre.2000.0126","volume":"14","author":"JE Anderson","year":"2000","unstructured":"Anderson JE (2000) Bone marrow transplantation for myelodysplasia. Blood Rev 14: 63\u201377","journal-title":"Blood Rev"},{"key":"BF03041035_CR102","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2000.02200.x","volume":"110","author":"T Witte de","year":"2000","unstructured":"de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley J (2000) Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukemias: a report on behalfe of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110: 620\u2013630","journal-title":"Br J Haematol"},{"key":"BF03041035_CR103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bmt.1701084","volume":"21","author":"V Runde","year":"1998","unstructured":"Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J (1998) Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 255\u2013261","journal-title":"Bone Marrow Transplant"},{"key":"BF03041035_CR104","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V87.1.51.51","volume":"87","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R (1996) Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimensand analysis of prognostic factors. Blood 87: 51\u201358","journal-title":"Blood"},{"key":"BF03041035_CR105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","volume":"95","author":"HJ Deeg","year":"2000","unstructured":"Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, Appelbaum FR (2000) Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95: 1188\u20131194","journal-title":"Blood"},{"key":"BF03041035_CR106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2141.1996.4811022.x","volume":"93","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, Buckner CD, Sanders JE, Sullivan KM, Storb R (1996) Unrelated bone marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol 93: 59\u201367","journal-title":"Br J Haematol"},{"key":"BF03041035_CR107","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bmt.1701269","volume":"21","author":"R Arnold","year":"1998","unstructured":"Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Gratwohl A, Apperley JF (1998) Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21: 1213\u20131216","journal-title":"Bone Marrow Transplant"},{"key":"BF03041035_CR108","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM199303043280901","volume":"328","author":"NA Kernan","year":"1993","unstructured":"Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, et al (1993) Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328: 593\u2013602","journal-title":"N Engl J Med"},{"key":"BF03041035_CR109","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2141.1996.d01-1479.x","volume":"92","author":"H Demuynck","year":"1996","unstructured":"Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, Van den Berghe H, Boogaerts MA (1996) Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92: 351\u2013359","journal-title":"Br J Haematol"},{"key":"BF03041035_CR110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.1996.7292351.x","volume":"95","author":"AM Carella","year":"1996","unstructured":"Carella AM, Dejana A, Lerma E (1996) In vivo mobilisation of karyotypically normal peripheral blood progenitor cells in high risk MDS, secondary or therapy-related acute myelogenous leukemia. Br J Haematol 95: 127\u2013130","journal-title":"Br J Haematol"},{"key":"BF03041035_CR111","first-page":"52","volume":"21","author":"E Wattel","year":"1997","unstructured":"Wattel E, Solary E, Caillot D, et al (1997) Autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leuk Res [Suppl 21]: 52","journal-title":"Leuk Res"},{"key":"BF03041035_CR112","first-page":"3853","volume":"90","author":"T Witte de","year":"1997","unstructured":"de Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri SB, Carelly A, Apperley J, Gratwohl A, Laporte JP (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90: 3853\u20133857","journal-title":"Blood"},{"key":"BF03041035_CR113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00062752-199811000-00019","volume":"5","author":"MA Boogaerts","year":"1998","unstructured":"Boogaerts MA (1998) Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia. Curr Opin Hematol 5: 465\u2013471","journal-title":"Curr Opin Hematol"},{"issue":"Suppl","key":"BF03041035_CR114","first-page":"152a","volume":"25","author":"T Witte de","year":"2000","unstructured":"de Witte T, Van Biezen A, Hermans J, et al (2000) Autologous stem cell transplantation for patients with MDS and AML following MDS. Bone Marrow Transplant 25 [Suppl]: 152a","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl","key":"BF03041035_CR115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/shem.2002.35981","volume":"39","author":"R Kurzrock","year":"2002","unstructured":"Kurzrock R (2002) Myelodysplastic syndrome. Overview. Semin Hematol 39 [Suppl]: 18\u201325","journal-title":"Semin Hematol"},{"key":"BF03041035_CR116","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","volume":"50","author":"J Cortes","year":"2002","unstructured":"Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50: 497\u2013500","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF03041035_CR117","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","volume":"94","author":"DC Matthews","year":"1999","unstructured":"Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R, Bernstein ID (1999) Phase I study of131I-anti-CD45 antibody plus cyclophopshamide and total body irradiation for advanced acute myeloid leukemia and myelodysplastic syndrome. Blood 94: 1237\u20131247","journal-title":"Blood"},{"key":"BF03041035_CR118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/shem.2002.36925","volume":"39","author":"R Kurzrock","year":"2002","unstructured":"Kurzrock R, Cortes J, Kantarjian H (2002) Clinical development of farnesyl-transferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 39: 20\u201324","journal-title":"Semin Hematol"},{"key":"BF03041035_CR119","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10428199509107898","volume":"19","author":"G Visani","year":"1995","unstructured":"Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S (1995) All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 19: 277\u2013280","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002770050488","volume":"78","author":"WK Hofmann","year":"1999","unstructured":"Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G, Hoffmann K, Hoffken K, Fischer JT, Isele G, Hoelzer D (1999) Treatment of patients with low risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 78: 125\u2013130","journal-title":"Ann Hematol"},{"key":"BF03041035_CR121","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood.V99.5.1578","volume":"99","author":"R Stasi","year":"2002","unstructured":"Stasi R, Brunetti M, Terzoli E, Amadori S (2002) Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99: 1578\u20131584","journal-title":"Blood"},{"key":"BF03041035_CR122","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2002-01-0165","volume":"100","author":"MK Magnusson","year":"2002","unstructured":"Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE (2002) Acitivity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100: 1088\u20131091","journal-title":"Blood"},{"key":"BF03041035_CR123","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"15","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silbjerman S, Schulheis B, Cross NC, Goldman JM (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 15: 481\u2013487","journal-title":"N Engl J Med"},{"key":"BF03041035_CR124","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V90.4.1403","volume":"90","author":"T Uchida","year":"1997","unstructured":"Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, Murate T (1997) Hypermethylation of p151NK4B gene in myelodysplastic syndromes. Blood 90: 1403\u20131409","journal-title":"Blood"},{"key":"BF03041035_CR125","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V91.8.2985.2985_2985_2990","volume":"91","author":"B Quesnel","year":"1998","unstructured":"Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91: 2985\u20132990","journal-title":"Blood"},{"issue":"Suppl","key":"BF03041035_CR126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0145-2126(98)00039-3","volume":"1","author":"BD Cheson","year":"1998","unstructured":"Cheson BD (1998) Standard and low dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 1 [Suppl]: 17\u201321","journal-title":"Leuk Res"},{"key":"BF03041035_CR127","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P Wijermans","year":"2000","unstructured":"Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956\u2013962","journal-title":"J Clin Oncol"},{"key":"BF03041035_CR128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","volume":"98","author":"A Raza","year":"2001","unstructured":"Raza A, Meyer P, Dutt D, Zorat F, Lisac L, Nascimben F, duRandt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958\u2013965","journal-title":"Blood"},{"key":"BF03041035_CR129","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03204.x","volume":"115","author":"F Zorat","year":"2001","unstructured":"Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115: 881\u2013894","journal-title":"Br J Haematol"},{"key":"BF03041035_CR130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","volume":"16","author":"C Strupp","year":"2002","unstructured":"Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16: 1\u20136","journal-title":"Leukemia"},{"key":"BF03041035_CR131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/07357909609012155","volume":"14","author":"HH Gerhartz","year":"1996","unstructured":"Gerhartz HH, Zwierzina HH, Walther J, Fenaux P, Hayat M, Jacobs A, Hoffbrand AV, Dardenne M, Solbu G, Suciu S (1996) Interleukin-3 plus low dose cytosine arabinoside for advanced myelodysplasia: a pilot study: EORTC Leukemia Group. Cancer Invest 14: 299\u2013306","journal-title":"Cancer Invest"},{"key":"BF03041035_CR132","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10428199809058394","volume":"29","author":"R Nair","year":"1998","unstructured":"Nair R, Nair CN, Advani SH (1998) All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome. Leuk Lymphoma 29: 187\u2013192","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR133","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/sj.leu.2401425","volume":"13","author":"A Kikuchi","year":"1999","unstructured":"Kikuchi A, Ohashi H, Hanada R, Yamamoto K (1999) Low-dose cytarabine (LD-AraC) plus recombinant human granulocyte colony-stimulating factor (G-CSF) for myelodysplastic syndromes (MDS). Leukemia 13: 980\u2013981","journal-title":"Leukemia"},{"key":"BF03041035_CR134","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-112-12-932","volume":"112","author":"BD Cheson","year":"1990","unstructured":"Cheson BD (1990) The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med 112: 932\u2013941","journal-title":"Ann Intern Med"},{"key":"BF03041035_CR135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0145-2126(97)00149-5","volume":"22","author":"DC Doll","year":"1998","unstructured":"Doll DC, Kasper LM, Taetle R, List AF (1998) Treatment with low-dose etoposide in patients with myelodysplastic syndromes. Leuk Res 22: 7\u201312","journal-title":"Leuk Res"},{"key":"BF03041035_CR136","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","volume":"31","author":"M Beran","year":"1998","unstructured":"Beran M, Estey E, O\u2019Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM, (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31: 521\u2013531","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR137","first-page":"609","volume":"10","author":"E Omoto","year":"1996","unstructured":"Omoto E, Deguchi S, Takaba S, Kojima K, Yano T, Katayama Y, Sunami K, Takeuchi M, Kimura F, Harada M, Kimura I (1996) Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 10: 609\u2013614","journal-title":"Leukemia"},{"key":"BF03041035_CR138","doi-asserted-by":"crossref","unstructured":"Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 22 [Suppl]: S17\u2013S22","DOI":"10.1016\/S0145-2126(98)00039-3"},{"key":"BF03041035_CR139","first-page":"3","volume":"36","author":"M Beran","year":"1999","unstructured":"Beran M, Kantarjian H (1999) Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin Hematol [Suppl 36]: 3\u201310","journal-title":"Semin Hematol"},{"key":"BF03041035_CR140","first-page":"560","volume":"27","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Zwiebel JA, Dancey J, Murgo A (2000) Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 27: 560\u2013577","journal-title":"Semin Oncol"},{"key":"BF03041035_CR141","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s002770100360","volume":"80","author":"Y Asano","year":"2001","unstructured":"Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K, Gondo H, Okamura T, Okamura S, Niho Y (2001) Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 80: 634\u2013638","journal-title":"Ann Hematol"},{"key":"BF03041035_CR142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","volume":"99","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99: 699\u2013705","journal-title":"Br J Haematol"},{"key":"BF03041035_CR143","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO;2-Y","volume":"79","author":"DH Biesma","year":"1997","unstructured":"Biesma DH, van den Tweel JG, Verdonck LF (1997) Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79: 1548\u20131551","journal-title":"Cancer"},{"key":"BF03041035_CR144","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1046\/j.1365-2141.1998.00920.x","volume":"102","author":"JJ Molldrem","year":"1998","unstructured":"Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ (1998) Haematological reponse of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102: 1314\u20131322","journal-title":"Br J Haematol"},{"key":"BF03041035_CR145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2141.1999.01187.x","volume":"104","author":"CG Geary","year":"1999","unstructured":"Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh JC (1999) Abnormal cytogenetic clones in patients with aplastic anemia: response to immunosuppressive therapy. Br J Haematol 104: 271\u2013274","journal-title":"Br J Haematol"},{"key":"BF03041035_CR146","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0609.2002.01625.x","volume":"68","author":"M Aivado","year":"2002","unstructured":"Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C, Novotny J, Josten KM, Kobbe G, Hildebrandt B, Gattermann N, Aul C, Haas R, Ganser A (2002) Favorable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a non-clonal pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68: 210\u2013216","journal-title":"Eur J Haematol"},{"key":"BF03041035_CR147","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574","volume":"100","author":"Y Saunthararajah","year":"2002","unstructured":"Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewiski JP, Simonis T, Molldrem J, Young NS, Barrett AJ (2002) HLA-DR15 (DR2) is overexpressed in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100: 1570\u20131574","journal-title":"Blood"},{"key":"BF03041035_CR148","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2002-09-2867","volume":"101","author":"DP Steensma","year":"2003","unstructured":"Steensma DP, Dispenzieri A, Moore SB, Schroder G, Tefferi A (2003) Antithymocyte globulin has limited efficacy and substantial toxicity in unselected patients with myelodysplastic syndrome. Blood 101: 2156\u20132158","journal-title":"Blood"},{"key":"BF03041035_CR149","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","volume":"120","author":"SB Killick","year":"2003","unstructured":"Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia. Br J Haematol 120: 679\u2013684","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"BF03041035_CR150","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0145-2126(98)00034-4","volume":"22","author":"AF List","year":"1998","unstructured":"List AF (1998) Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? Leuk Res 22 [Suppl 1]: S7-S11","journal-title":"Leuk Res"},{"key":"BF03041035_CR151","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1182\/blood.V90.9.3364","volume":"90","author":"AF List","year":"1997","unstructured":"List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364\u20133369","journal-title":"Blood"},{"key":"BF03041035_CR152","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/sj.leu.2401151","volume":"12","author":"AF List","year":"1998","unstructured":"List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL (1998) Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12: 1596\u20131602","journal-title":"Leukemia"},{"key":"BF03041035_CR153","first-page":"322","volume":"87","author":"A Grossi","year":"2002","unstructured":"Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, Sanpaolo G (2002) Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica 87: 322\u2013323","journal-title":"Haematologica"},{"key":"BF03041035_CR154","first-page":"367","volume":"85","author":"A Grossi","year":"2000","unstructured":"Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, Pagliai G, Ciolli S, Rossi Ferrini P (2000) Amifostine in the treatment of low-risk myelodysplastic syndromes. Heematologica 85: 367\u2013371","journal-title":"Heematologica"},{"key":"BF03041035_CR155","first-page":"35","volume":"9","author":"AF List","year":"1999","unstructured":"List AF (1999) Pharmacological differentiation and antiapoptotic therapy in myelodysplastic syndromes. Forum (Genova) 9: 35\u201345","journal-title":"Forum (Genova)"},{"issue":"Suppl 3","key":"BF03041035_CR156","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ard.60.90003.iii41","volume":"60","author":"P Greenberg","year":"2001","unstructured":"Greenberg P (2001) Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Ann Rheum Dis 60 [Suppl 3]: 41\u201342","journal-title":"Ann Rheum Dis"},{"key":"BF03041035_CR157","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/jir.1998.18.871","volume":"18","author":"S Reza","year":"1998","unstructured":"Reza S, Shetty V, Dar S, Qwai H, Raza A (1998) Tumor necrosis factor-alpha levels decrease with anti-cytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18: 871\u2013877","journal-title":"J Interferon Cytokine Res"},{"key":"BF03041035_CR158","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/10245332.2000.11746517","volume":"5","author":"A Raza","year":"2000","unstructured":"Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang RW, Venugopal P, Gezer S, Gregory SA, Hsu WT, Loew J, Robin E, Rifkin S, Shah R, Divgi A, Taylor R, Grosset A (2000) Pentoxifylline, ciprofloxacin, and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients: malignancy. Hematology 5: 275\u2013284","journal-title":"Hematology"},{"key":"BF03041035_CR159","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V95.5.1580.005k45_1580_1587","volume":"95","author":"A Raza","year":"2000","unstructured":"Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu WT, Huang RW (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline and ciprofloxacin with or without dexamethasone. Blood 95: 1580\u20131587","journal-title":"Blood"},{"key":"BF03041035_CR160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.1984.tb06081.x","volume":"58","author":"G Tricot","year":"1984","unstructured":"Tricot G, De Bock R, Dekker AW, Boogarts MA, Peetermans M, Punt K, Verwilghen RL (1984) Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br J Haematol 58: 231\u2013240","journal-title":"Br J Haematol"},{"key":"BF03041035_CR161","first-page":"575","volume":"1","author":"BJ Bolwell","year":"1987","unstructured":"Bolwell BJ, Cassileth PA, Gale RP (1987) Low dose cytosine arabinoside in myelodydsplastia and acute myelogenous leukemia: a review. Leukemia 1: 575\u2013579","journal-title":"Leukemia"},{"key":"BF03041035_CR162","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0609.1988.tb00855.x","volume":"40","author":"E Hellstr\u00f6m","year":"1988","unstructured":"Hellstr\u00f6m E, Robert KH, Gahrton G, Mellstedt H, Lindemalm C, Einhorn S, Bjorkholm M, Grimfors G, Uden AM, Samuelsson J, et al (1988) Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvirtamin D3 and retinoic acid ion acute leukemia and myelodysplastic syndromes. Eur J Haematol 40: 449\u2013459","journal-title":"Eur J Haematol"},{"key":"BF03041035_CR163","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000226842","volume":"47","author":"I Schwarzinger","year":"1990","unstructured":"Schwarzinger I, Stain C, Bettelheim P, Hinterberger W, Lechner K (1990) Gamma-interferon in myelodysplastic syndromes: a pilot study. Oncology 47: 322\u2013326","journal-title":"Oncology"},{"key":"BF03041035_CR164","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V78.7.1658.1658","volume":"78","author":"RS Stein","year":"1991","unstructured":"Stein RS, Abels RI, Krantz SB (1991) Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78: 1658\u20131663","journal-title":"Blood"},{"key":"BF03041035_CR165","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0925-5710(96)00562-2","volume":"65","author":"RG Geissler","year":"1997","unstructured":"Geissler RG, Schulte P, Ganser A (1997) Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Int J Hematol 65: 339\u2013354","journal-title":"Int J Hematol"},{"key":"BF03041035_CR166","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2141.1995.tb08421.x","volume":"89","author":"EH Rose","year":"1995","unstructured":"Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anemia related to myelodysplasia (MDS). Br J Haematol 89: 831\u2013837","journal-title":"Br J Haematol"},{"key":"BF03041035_CR167","first-page":"733","volume":"3","author":"R Stasi","year":"1997","unstructured":"Stasi R, Brunetti M, Bussa S, Conforti M, DiGiulio C, Crescenzi A, Terzoli E, Vecchione A, Pagano A (1997) Response to recombinant human erythropoietin in patients with myelodysplatic syndromes. J Clin Cancer Res 3: 733\u2013739","journal-title":"J Clin Cancer Res"},{"key":"BF03041035_CR168","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","volume":"89","author":"E Hellstr\u00f6m-Lindberg","year":"1995","unstructured":"Hellstr\u00f6m-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 trials. Br J Haematol 89: 67\u201371","journal-title":"Br J Haematol"},{"key":"BF03041035_CR169","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","volume":"103","author":"Italian cooperative study group for rHuEPO in myelodysplastic syndromes","year":"1998","unstructured":"Italian cooperative study group for rHuEPO in myelodysplastic syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103: 1070\u20131074","journal-title":"Br J Haematol"},{"key":"BF03041035_CR170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0145-2126(00)00073-4","volume":"25","author":"R Hast","year":"2001","unstructured":"Hast R, Wallvik J, Folin A, Bernell P, Stenke L (2001) Long term follow up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 25: 13\u201318","journal-title":"Leuk Res"},{"key":"BF03041035_CR171","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V76.1.36.36","volume":"76","author":"RS Negrin","year":"1990","unstructured":"Negrin RS, Haeubner DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colonystimulating factor. Blood 76: 36\u201343","journal-title":"Blood"},{"key":"BF03041035_CR172","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02173523","volume":"2","author":"K Tamura","year":"1990","unstructured":"Tamura K, Takeuchi M, Hirakawa N, Toyoda K, Minoda M (1990) Successful treatment for perinephric abscess with recombinant human granulocyte colony-stimulating factor following nephrectomy in a patient of myelodysplastic syndrome: a case report. Biotherapy 2: 223\u2013226","journal-title":"Biotherapy"},{"key":"BF03041035_CR173","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM198712173172501","volume":"317","author":"S Vadhan-Raj","year":"1987","unstructured":"Vadhan-Raj S, Keating M, LeMaistre A, Hittleman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Guttermann JU (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545\u20131552","journal-title":"N Engl J Med"},{"key":"BF03041035_CR174","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V73.1.31.31","volume":"73","author":"A Ganser","year":"1989","unstructured":"Ganser A, Volkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Blood 73: 31\u201337","journal-title":"Blood"},{"key":"BF03041035_CR175","first-page":"199","volume":"9","author":"PL Greenberg","year":"1990","unstructured":"Greenberg PL, Negrin R, Nagler A (1990) The use of haematopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surv 9: 199\u2013212","journal-title":"Cancer Surv"},{"key":"BF03041035_CR176","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0145-2126(95)00131-X","volume":"20","author":"HI Saba","year":"1996","unstructured":"Saba HI (1996) Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk Res 20: 203\u2013219","journal-title":"Leuk Res"},{"key":"BF03041035_CR177","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/10428199709058596","volume":"1","author":"A Ganser","year":"1997","unstructured":"Ganser A, Karthaus M (1997) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 1: 13\u201327","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR178","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V82.3.737.737","volume":"82","author":"S Negrin","year":"1993","unstructured":"Negrin S, Stein R, Vardiman J, Doherty K, Cornwall J, Krantz S, Greenberg L (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737\u2013743","journal-title":"Blood"},{"key":"BF03041035_CR179","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428199309086999","volume":"11","author":"E Hellstr\u00f6m-Lindberg","year":"1993","unstructured":"Hellstr\u00f6m-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I, et al (1993) A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11: 221\u2013228","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR180","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","volume":"87","author":"S Negrin","year":"1996","unstructured":"Negrin S, Stein R, Doherty K, Cornwall J, Vardiman J, Krantz S, Greenberg L (1996) Maintainance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076\u20134081","journal-title":"Blood"},{"key":"BF03041035_CR181","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","volume":"99","author":"E Hellstr\u00f6m-Lindberg","year":"1997","unstructured":"Hellstr\u00f6m-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99: 344\u2013351","journal-title":"Br J Haematol"},{"key":"BF03041035_CR182","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","volume":"92","author":"E Hellstr\u00f6m-Lindberg","year":"1998","unstructured":"Hellstr\u00f6m-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, L\u00f6fenberg E, Nielsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, \u00d6berg G, \u00d6sterborg A, \u00d6st A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colonystimulating factor plus erythropoietin: results from a randomized phase II study and long term follow-up of 71 patients. Blood 92: 68\u201375","journal-title":"Blood"},{"key":"BF03041035_CR183","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.leu.2401442","volume":"13","author":"T Economopoulos","year":"1999","unstructured":"Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S (1999) Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant erythropoietin. Leukemia 13: 1009\u20131012","journal-title":"Leukemia"},{"key":"BF03041035_CR184","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","volume":"95","author":"JA Thompson","year":"2000","unstructured":"Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt C, Nelson RA, Rose EH, Dugan MH (2000) Effect of recombinant human erythropoietin combined with granulocyte-macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95: 1175\u20131179","journal-title":"Blood"},{"key":"BF03041035_CR185","first-page":"44","volume":"86","author":"P Musto","year":"2001","unstructured":"Musto P, Sanpaolo G, D\u2019Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M (2001) Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-depedent patients with myelody splastic syndromes unresponsive to erythropoietin alone. Hematologica 86: 44\u201351","journal-title":"Hematologica"},{"key":"BF03041035_CR186","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0145-2126(98)00057-5","volume":"22","author":"EC Besa","year":"1998","unstructured":"Besa EC, Kunselman S, Nowell PC, The Central Pennsylvania Oncology Group (1998) A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. Leuk Res 22: 741\u2013749","journal-title":"Leuk Res"},{"key":"BF03041035_CR187","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(00)00108-9","volume":"25","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L (2001) Amifostine alone and in combination with erythropoietin for the treatment of favourable myelodysplatic syndrome. Leuk Res 25: 183\u2013185","journal-title":"Leuk Res"},{"key":"BF03041035_CR188","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","volume":"120","author":"D Bowen","year":"2003","unstructured":"Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120: 187\u2013200","journal-title":"Br J Haematol"},{"key":"BF03041035_CR189","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2002-06-1767","volume":"100","author":"JD Rizzo","year":"2002","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoietin in patients with cancer: evidence-based clinical guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303\u20132320","journal-title":"Blood"},{"key":"BF03041035_CR190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"E Estey","year":"1994","unstructured":"Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O\u2019Brian S, Escudier S, Robertson LE, Koller C, Kornblau S, et al (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenousleukemia or myelodysplastic syndrome: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671\u2013678","journal-title":"J Clin Oncol"},{"key":"BF03041035_CR191","first-page":"215","volume":"60","author":"T Im","year":"1994","unstructured":"Im T, Yamane T, Mugitani A, Hiyoshi M, Park K, Tatsumi N (1994) Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic plase. Int J Hematol 60: 215\u2013223","journal-title":"Int J Hematol"},{"key":"BF03041035_CR192","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10428199709068275","volume":"27","author":"TJ Nokes","year":"1997","unstructured":"Nokes TJ, Johnson S, Harvey D, Goldstone AH (1997) FLAG is a useful regiment for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma 27: 93\u2013101","journal-title":"Leuk Lymphoma"},{"key":"BF03041035_CR193","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/sj.leu.2401425","volume":"13","author":"A Kikuchi","year":"1999","unstructured":"Kikuchi A, Ohashi H, Hanada R, Yamamoto K (1999) Low-dose cytarabine (LD-AraC) plus recombinant human granulocyte colony-stimulating factor (rhG-SCF) for myelodysplastic syndromes (MDS). Leukemia 13: 980\u2013981","journal-title":"Leukemia"},{"key":"BF03041035_CR194","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","volume":"18","author":"H Ozer","year":"2000","unstructured":"Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo AP, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558\u20133585","journal-title":"J Clin Oncol"},{"key":"BF03041035_CR195","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","volume":"100","author":"DJ Kuter","year":"2002","unstructured":"Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100: 3457\u20133469","journal-title":"Blood"},{"key":"BF03041035_CR196","first-page":"173","volume":"72","author":"K Ogata","year":"2000","unstructured":"Ogata K, Tamura H (2000) Thrombopoietin and myelodysplastic syndromes. Int J Hematol 72: 173\u2013177","journal-title":"Int J Hematol"},{"key":"BF03041035_CR197","first-page":"296","volume":"96","author":"N Komatsu","year":"2000","unstructured":"Komatsu N, Okamoto T, Yoshida T, et al (2000) Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) Blood 96: 296a","journal-title":"Blood"},{"key":"BF03041035_CR198","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2001.19.21.4165","volume":"19","author":"R Kurzrock","year":"2001","unstructured":"Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M (2001) Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 19: 4165\u20134172","journal-title":"J Clin Oncol"},{"key":"BF03041035_CR199","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, L\u00f6wenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization (WHO) international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671\u20133674","journal-title":"Blood"}],"container-title":["Wiener Klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03041035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03041035\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03041035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:42:06Z","timestamp":1739101326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03041035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":199,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["BF03041035"],"URL":"https:\/\/doi.org\/10.1007\/bf03041035","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}